Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig C Earle

Showing results (261-270 of 288) with videos related to

Pageof 29
Sort By:
Cancer Chemotherapy and Pharmacology|June 21, 2006
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancerAndrew X Zhu, Jeffrey W Clark, David P Ryan, et al.
Cancer Medicine|March 31, 2023
Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilizationBrandon Lu, Wei Fang Dai, Ruth Croxford, et al.
Cancers|May 27, 2026
Population-Level Resources and Costs Associated with Low-Risk Prostate Cancer Patients on Active SurveillanceSoo Jin Seung, Jane Bayani, Lena Nguyen, et al.
JAMA Network Open|February 27, 2024
Socioeconomic Status, Palliative Care, and Death at Home Among Patients With Cancer Before and During COVID-19Javaid Iqbal, Rahim Moineddin, Robert A Fowler, et al.
JNCI Cancer Spectrum|June 27, 2022
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic CancerVanessa Arciero, Jin Luo, Ambica Parmar, et al.
JCO Oncology Practice|February 10, 2023
Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic SyndromesLee Mozessohn, Qing Li, Ning Liu, et al.
Eclinicalmedicine|February 3, 2026
Palliative care, socioeconomic position, and end-of-life cancer quality outcomes: a mediation analysisJavaid Iqbal, Rahim Moineddin, Robert A Fowler, et al.
Journal of the National Cancer Institute|October 18, 2015
The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population StudyHart A Goldhar, Andrew T Yan, Dennis T Ko, et al.
Breast Cancer Research and Treatment|June 9, 2016
Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based studyInna Y Gong, Sunil Verma, Andrew T Yan, et al.
Annals of Hematology|February 22, 2022
The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromesEugene Brailovski, Qing Li, Ning Liu, et al.
Pageof 29

Showing results (261-270 of 288) with videos related to

Sort By:
Pageof 29
Cancer Chemotherapy and Pharmacology|June 21, 2006
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancerAndrew X Zhu, Jeffrey W Clark, David P Ryan, et al.
Cancer Medicine|March 31, 2023
Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilizationBrandon Lu, Wei Fang Dai, Ruth Croxford, et al.
Cancers|May 27, 2026
Population-Level Resources and Costs Associated with Low-Risk Prostate Cancer Patients on Active SurveillanceSoo Jin Seung, Jane Bayani, Lena Nguyen, et al.
JAMA Network Open|February 27, 2024
Socioeconomic Status, Palliative Care, and Death at Home Among Patients With Cancer Before and During COVID-19Javaid Iqbal, Rahim Moineddin, Robert A Fowler, et al.
JNCI Cancer Spectrum|June 27, 2022
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic CancerVanessa Arciero, Jin Luo, Ambica Parmar, et al.
JCO Oncology Practice|February 10, 2023
Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic SyndromesLee Mozessohn, Qing Li, Ning Liu, et al.
Eclinicalmedicine|February 3, 2026
Palliative care, socioeconomic position, and end-of-life cancer quality outcomes: a mediation analysisJavaid Iqbal, Rahim Moineddin, Robert A Fowler, et al.
Journal of the National Cancer Institute|October 18, 2015
The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population StudyHart A Goldhar, Andrew T Yan, Dennis T Ko, et al.
Breast Cancer Research and Treatment|June 9, 2016
Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based studyInna Y Gong, Sunil Verma, Andrew T Yan, et al.
Annals of Hematology|February 22, 2022
The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromesEugene Brailovski, Qing Li, Ning Liu, et al.
Pageof 29